Amanda Forys | Managing Partner
Magnolia Market Access

Amanda Forys, Managing Partner, Magnolia Market Access

Amanda Forys is Managing Partner at Magnolia Market Access. Her consulting and manufacturer experience has covered a wide range of commercialization topics, including health policy, pricing and rebating, coding, coverage and reimbursement, health economics, budget impact modeling, patient assistance design, and training for specialty pharmaceuticals, biosimilars, organ transplantation, and devices. Amanda often uses quantitative methods for her strategic work, utilizing public and private claims data sources for payment system modeling, budget scoring, and chronic disease studies. Her work, coupled with the invaluable insights gathered by her colleagues through primary and secondary research, provides Magnolia’s clients with a comprehensive look at the marketplace throughout their product’s life cycle. Prior to joining Magnolia, Amanda worked for United Therapeutics, a manufacturer of specialty drugs for orphan diseases and organ transplantation products. She also has over a decade of consulting experience, working for manufacturers and trade associations. Amanda serves as a national speaker on healthcare and has represented her previous company and clients in meetings with members of Congress, CMS, CBO, OMB, and MedPAC. Amanda received her Master of Science in Public Health from the University of North Carolina at Chapel Hill, with a concentration in health policy and administration. During this time, she completed an internship with the GAO’s healthcare team. She has a Bachelor of Science in biopsychology and cognitive sciences and a Bachelor of Arts in voice performance from the University of Michigan at Ann Arbor.  

Appearances:



Day 2 - World Orphan Drug Congress USA 2025 @ 10:40

Panel: Optimizing Strategies for Orphan Drug Access and Reimbursement: Considerations for Raising Venture Capital through Commercialization

In this panel discussion, experts will share perspective best strategies for optimizing market access, pricing and reimbursement of orphan drugs.  The session will cover considerations from early-stage drug development through commercial launch.  Panelists will explore key challenges to developing and executing a multi-stakeholder strategy across multiple orphan therapeutic areas.  Attendees will gain insights onto creating value-added market access and reimbursement strategies for investor and strategic stakeholders that bolster access to novel, life-changing therapies while ensuring corporate viability.

last published: 24/Apr/25 11:35 GMT

back to speakers

Get Involved At World Orphan Drug Congress USA

 

Connect with us

 
 
 
 

 

To Sponsor Or Exhibit

 
 

Justin Franks
justin.franks@terrapinn.com
t/ +1 914 819 3506

 

 

 

To Speak

 
 

Kaylee Nguyen
kaylee.nguyen@terrapinn.com
 

 

 

 

Marketing & Press

 
 

Kaylie Brogan
kaylie.brogan@terrapinn.com